@drcamidge.bsky.social’s incredible presentation from #TTLC26 is now available online. Anyone who deals with cancer in any capacity should watch it. You might cry (I did) but it’s worth it. Thank you IASLC for making the presentation publicly available. m.youtube.com/watch?v=cnh5...

The U Colorado lung medical oncology team as from today at the Targeted Therapies of Lung Cancer meeting in California.

I’d never cried at a conference until today. Ross, thank you for this incredible talk. You’re a wonderful human, clinician, researcher, boss, mentor, and friend. The standing ovation was more than deserved. @drcamidge.bsky.social @cucancercenter.bsky.social #TTLC26

I’m officially a board-certified medical oncologist!

Congratulations to everyone who matched today! I look forward to working with our newest @cuhemeonc.bsky.social fellows!

The cover story from the fall 2025 issue of the C3: CU Cancer Center's @drcamidge.bsky.social, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a lung cancer diagnosis of his own. Read his story: https://bit.ly/47yGdBb

Continuing ALK TKIs when starting chemotherapy for disease progression improves outcomes in patients with advanced ALK+ NSCLC. We were happy to be able to contribute to this important project. jnccn.org/view/journal...

CU Cancer Center member Tejas Patil, MD, enrolled Jennifer Brown in a clinical trial of a new type of immunotherapy to treat her lung cancer that had spread to her bones, liver, and brain. Brown had a remarkable response to the treatment ⬇️ https://bit.ly/47PaslL

Medical Oncology Board Exam ✅

The Colorado Public Radio interview with Andrea Dukakis aired this week. Andrea had lost her daughter to a brain tumor and so cancer is something that has touched her and her family directly. www.cpr.org/2025/10/28/l...

Paul Bunn, MD, inaugural director, and @drcamidge.bsky.social, MD, PhD, director of thoracic oncology, both share what has changed during their time with the CU Cancer Center and what the next 40 years can bring ⬇️

It was a pleasure attending and speaking at the 2025 Seattle Lung Cancer Conference. The 🫁 were truly front and center! @binaytara.bsky.social #SeattleLung25

Watching @drcamidge.bsky.social navigate this cruel twist of fate for the last few years has been nothing short of inspirational. Becoming a lung cancer patient himself has made him an even better clinician, researcher, and advocate. I’m very fortunate to be able to learn from him.

Last day of clinic at the VA. It’s been an honor taking care of the veterans here for the last 2.5 years. I’ll miss my patients and the team in the hematology/oncology clinic.

It’s getting real! I’m honored to soon be sharing an office with my mentor at @cucancercenter.bsky.social

Tarlatamab is clearly the best 2nd line therapy for small cell lung cancer available now. I’m excited to see this and similar agents develop and perhaps move into the 1st line. #ASCO2025

Neoadjuvant treatment with chemo-immunotherapy is clearly the new standard of care for most patients with resectable non-small cell lung cancer. The question remains what (if any) is the best adjuvant therapy for these patients? #ASCO2025

Exercise reduces the risk of cancer recurrence and improves survival after colon cancer treatment. I suspect that this is also true in other cancers. This should be one of the most impactful trials to come out of #ASCO2025!

I applaud these authors for trying to answer a very tricky question. I don’t quite know what to make of their numbers given the many unknowns and confounders, but I do believe that CTs increase cancer risk and that we could (and probably should) do less of them.

@drcamidge.bsky.social have you ever encountered central necrosis in your time in the oncologist’s garden?